DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: For example, molecular confirmation of dystrophinopathy determines applicability of corticosteroid therapy, as DMD is one of the MDs showing fruitful results from this treatment (Albuquerque et al., 2014; Bello et al., 2015).